Costantine MM, et al. - Researchers examined how antenatal treatment of subclinical hypothyroidism affects maternal depressive symptoms. This is an ancillary study to a multicenter trial including women with singleton pregnancies diagnosed with subclinical hypothyroidism randomized to antenatal thyroxine therapy or placebo. They assessed 245 (36.2% of parent trial) women with subclinical hypothyroidism; of these, 124 were allocated to thyroxine or 121 were allocated to placebo. The Center for Epidemiological Studies-Depression scale was employed for assessment of participants for depressive symptoms before starting the study drug (between 11 and 20 weeks of gestation), between 32 and 38 weeks of gestation, and at 1 year postpartum. Outcomes suggest that this cohort of pregnant women with subclinical hypothyroidism had no improvement in maternal depressive symptoms in correlation to receiving antenatal thyroxine replacement.